Importantly, DEG-KRAS also exerted bystander effects in recipient cells via EV transfer, which may help address a major limitation of gene therapy—namely, the difficulty of delivering therapeutic genes to all tumor cells. The gene discussed is KRAS; the disease is neoplasm.